Published in Clin Liver Dis on February 01, 2003
Adaptive mutations producing efficient replication of genotype 1a hepatitis C virus RNA in normal Huh7 cells. J Virol (2004) 2.76
Gene transfer in the evolution of parasite nucleotide biosynthesis. Proc Natl Acad Sci U S A (2004) 2.05
Induction of interferon-stimulated gene expression and antiviral responses require protein deacetylase activity. Proc Natl Acad Sci U S A (2004) 2.04
Effective treatment of injecting drug users with recently acquired hepatitis C virus infection. Gastroenterology (2009) 1.99
Alternative approaches for efficient inhibition of hepatitis C virus RNA replication by small interfering RNAs. J Virol (2004) 1.61
Virus-specific mechanisms of carcinogenesis in hepatitis C virus associated liver cancer. Oncogene (2011) 1.56
Dissecting the interferon-induced inhibition of hepatitis C virus replication by using a novel host cell line. J Virol (2005) 1.41
Tumor suppressors, chromosomal instability, and hepatitis C virus-associated liver cancer. Annu Rev Pathol (2009) 1.20
Effects of silymarin on hepatitis C virus and haem oxygenase-1 gene expression in human hepatoma cells. Liver Int (2008) 1.05
Comprehensive analysis of the effects of ordinary nutrients on hepatitis C virus RNA replication in cell culture. Antimicrob Agents Chemother (2007) 1.01
Transduction of human T cells with a novel T-cell receptor confers anti-HCV reactivity. PLoS Pathog (2010) 0.96
Do statins reduce hepatitis C RNA titers during routine clinical use? World J Gastroenterol (2009) 0.95
Y-box-binding protein 1 interacts with hepatitis C virus NS3/4A and influences the equilibrium between viral RNA replication and infectious particle production. J Virol (2011) 0.91
Interferon plus ribavirin and interferon alone in preventing hepatocellular carcinoma: a prospective study on patients with HCV related cirrhosis. World J Gastroenterol (2004) 0.88
Inhibition of core gene of HCV 3a genotype using synthetic and vector derived siRNAs. Virol J (2010) 0.88
Imbalance of regulatory T cells and T helper type 17 cells in patients with chronic hepatitis C. Immunology (2014) 0.86
Inhibition of hepatitis C virus replication by arsenic trioxide. Antimicrob Agents Chemother (2004) 0.85
Monocyte chemotactic protein-1 and soluble adhesion molecules as possible prognostic markers of the efficacy of antiviral treatment in chronic hepatitis C. World J Gastroenterol (2004) 0.85
Generation of immune responses against hepatitis C virus by dendritic cells containing NS5 protein-coated microparticles. Clin Vaccine Immunol (2008) 0.82
Host restriction factors for hepatitis C virus. World J Gastroenterol (2016) 0.78
Inhibition of hepatitis C virus replication by antimonial compounds. Antimicrob Agents Chemother (2005) 0.77
Down-regulation of IRES containing 5'UTR of HCV genotype 3a using siRNAs. Virol J (2011) 0.77
Short hairpin-looped oligodeoxynucleotides reduce hepatitis C virus replication. Virol J (2012) 0.75
Production of infectious HCV genotype 1b virus in cell culture using a novel Set of adaptive mutations. BMC Microbiol (2016) 0.75
A model of glycosylated human butyrylcholinesterase. Mol Biosyst (2014) 0.75
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med (2014) 7.73
Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med (2005) 7.18
Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med (2011) 6.31
Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology (2006) 4.90
Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response. Hepatology (2007) 3.87
Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol (2005) 3.10
Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models. Hepatology (2010) 2.28
Side effects of therapy for chronic hepatitis C. Gastroenterology (2003) 2.04
Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl (2004) 1.96
Patient and graft survival in hepatitis C recipients after adult living donor liver transplantation in the United States. Liver Transpl (2004) 1.74
Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction. Gastroenterology (2010) 1.74
Quantitation of pretreatment serum interferon-γ-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response. Hepatology (2011) 1.53
Delayed neuropsychologic dysfunction after liver transplantation for acute liver failure: a matched, case-controlled study. Liver Transpl (2002) 1.52
Defective hepatic response to interferon and activation of suppressor of cytokine signaling 3 in chronic hepatitis C. Gastroenterology (2006) 1.47
A global view of hepatitis C: physician knowledge, opinions, and perceived barriers to care. Hepatology (2013) 1.46
Severe villus atrophy and chronic malabsorption induced by azathioprine. Gastroenterology (2003) 1.46
Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD). J Hepatol (2002) 1.43
The FDA, bridging data, and hepatitis C. Hepatology (2013) 1.38
Silymarin ascending multiple oral dosing phase I study in noncirrhotic patients with chronic hepatitis C. J Clin Pharmacol (2009) 1.37
Pharmacokinetics and metabolic profile of free, conjugated, and total silymarin flavonolignans in human plasma after oral administration of milk thistle extract. Drug Metab Dispos (2007) 1.31
Early hepatic stellate cell activation is associated with advanced fibrosis after liver transplantation in recipients with hepatitis C. Liver Transpl (2005) 1.27
Maximizing opportunities and avoiding mistakes in triple therapy for hepatitis C virus. Gastroenterology (2012) 1.24
The pharmacokinetics of silymarin is altered in patients with hepatitis C virus and nonalcoholic Fatty liver disease and correlates with plasma caspase-3/7 activity. Drug Metab Dispos (2008) 1.17
Prospective analysis of depression during peginterferon and ribavirin therapy of chronic hepatitis C: results of the Virahep-C study. Am J Gastroenterol (2009) 1.16
Barriers to hepatitis C treatment. Liver Int (2012) 1.13
Early predictors of anemia in patients with hepatitis C genotype 1 treated with peginterferon alfa-2a (40KD) plus ribavirin. Am J Gastroenterol (2008) 1.11
Neurocognitive functioning and HAART in HIV and hepatitis C virus co-infection. AIDS (2006) 1.08
Social stigmatization and hepatitis C virus infection. J Clin Gastroenterol (2006) 1.05
Assessing the validity of self-reported medication adherence in hepatitis C treatment. Ann Pharmacother (2007) 1.04
A randomized controlled trial of an integrated care intervention to increase eligibility for chronic hepatitis C treatment. Am J Gastroenterol (2011) 1.03
High deferral rates and poorer treatment outcomes for HCV patients with psychiatric and substance use comorbidities. Dig Dis Sci (2007) 1.03
R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin. Hepatology (2008) 1.03
Pantoprazole reduces the size of postbanding ulcers after variceal band ligation: a randomized, controlled trial. Hepatology (2005) 1.00
Safety and antiviral activity of emtricitabine (FTC) for the treatment of chronic hepatitis B infection: a two-year study. J Hepatol (2005) 0.99
Certificate of added qualification for hepatology: vindication not vanity. Gastroenterology (2005) 0.96
Efficacy and safety of two-dose regimens of peginterferon alpha-2a compared with interferon alpha-2a in chronic hepatitis C: a multicenter, randomized controlled trial. Am J Gastroenterol (2004) 0.95
Medication use and medical comorbidity in patients with chronic hepatitis C from a US commercial claims database: high utilization of drugs with interaction potential. Eur J Gastroenterol Hepatol (2014) 0.93
Differences in the disposition of silymarin between patients with nonalcoholic fatty liver disease and chronic hepatitis C. Drug Metab Dispos (2011) 0.92
Rationale, challenges, and participants in a Phase II trial of a botanical product for chronic hepatitis C. Clin Trials (2011) 0.89
Prediction of sustained virological response in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) and ribavirin. Scand J Gastroenterol (2007) 0.88
Time to rethink antiviral treatment for hepatitis C in patients with coexisting mental health/substance abuse issues. Dig Dis Sci (2012) 0.87
Chronic hepatitis C and antiviral treatment regimens: where can psychology contribute? J Consult Clin Psychol (2012) 0.87
Unexpected maintenance of hepatitis C viral diversity following liver transplantation. J Virol (2012) 0.86
Tangible resources for preparing patients for antiviral therapy for chronic hepatitis C. Dig Dis Sci (2012) 0.86
Deep sequencing analysis of HCV NS3 resistance-associated variants and mutation linkage in liver transplant recipients. PLoS One (2013) 0.85
Persistent portosystemic shunts after liver transplantation causing episodic hepatic encephalopathy. Dig Dis Sci (2009) 0.84
Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients treated with interferon alpha for chronic hepatitis C. J Hepatol (2003) 0.83
High relapse rate seen at week 72 for patients treated with R1626 combination therapy. Hepatology (2008) 0.82
Guidelines for stopping therapy in chronic hepatitis C. Curr Gastroenterol Rep (2004) 0.82
Hepatitis C virus: a critical appraisal of approaches to therapy. Clin Gastroenterol Hepatol (2008) 0.81
Optimizing treatment regimens in hepatitis C. Clin Liver Dis (2006) 0.81
Randomized study of asunaprevir plus pegylated interferon-α and ribavirin for previously untreated genotype 1 chronic hepatitis C. Antivir Ther (2013) 0.81
Sustained virologic response rates with telaprevir-based therapy in treatment-naive patients evaluated by race or ethnicity. J Clin Gastroenterol (2015) 0.80
Social support and clinical outcomes during antiviral therapy for chronic hepatitis C. J Psychosom Res (2011) 0.80
Impact of donor age and year of transplant on graft survival in liver transplant recipients with chronic hepatitis C. Am J Transplant (2004) 0.80
Hepatitis C and alcohol: fundamental and translational research directions. Alcohol Clin Exp Res (2003) 0.79
Nitazoxanide: beyond parasites toward a novel agent for hepatitis C. Gastroenterology (2009) 0.79
Intensive interferon therapy does not increase virological response rates in African Americans with chronic hepatitis C. Dig Dis Sci (2003) 0.78
Chronic hepatitis B: a critical appraisal of current approaches to therapy. Clin Gastroenterol Hepatol (2006) 0.78
Management of newly diagnosed hepatitis C virus infection. Cleve Clin J Med (2003) 0.76
Hepatitis C: current options for nonresponders to peginterferon and ribavirin. Curr Gastroenterol Rep (2008) 0.76
Hepatitis C virus: a critical appraisal of new approaches to therapy. Hepat Res Treat (2012) 0.76
Response-guided therapy for acute hepatitis C: applying concepts from chronic treatment. Liver Int (2011) 0.75
The NIH roadmap for medical research: bypassing detours. Gastroenterology (2004) 0.75
Characteristics of US-Born Versus Foreign-Born Americans of African Descent With Chronic Hepatitis B. Am J Epidemiol (2017) 0.75
Metastatic leiomyosarcoma mimicking polycystic liver disease. Liver Transpl (2002) 0.75
Human investigations: Answering to an ever higher authority. Gastroenterology (2002) 0.75